publicações selecionadas
- Real-world data: evaluation of sentinel lymph node biopsy after complete pathological response of breast cancer to neoadjuvant chemotherapy in patients with triple-negative and her2 positive breast cancer in a cohort from rio grande do sul, brazil
- Implications of the PEARL trial from the low- to middle-income countries? perspectives
- Highlights of the 17th St. Gallen International Breast Cancer Conference 2021: customising local and systemic therapies
- Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil
- Prevalência da mutação de gene ESR1 em pacientes com câncer de mama receptor hormonal positivo resistentes à terapia endócrina neoadjuvante
- Machine learning prediction of COVID-19 mortality in cancer patients.
- Abstract OT2-22-02: Sequencing of anthracyclines and taxanes during neoadjuvant therapy of locally advanced HER2-negative breast cancer (NEOSAMBA Study/LACOG 0419)
- Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors
- Clinical implication of low estrogen receptor (ER-low) expression in breast cancer
- Multicenter database of patients with germ-cell tumors: a Latin American Cooperative Oncology Group Registry (LACOG 0515).
- Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil
- Open questions and controversies in the systemic treatment of breast cancer
- Sociodemographic and clinicopathologic features of elderly breast cancer patients in Brazil: A sub-analysis of AMAZONA III study (GBCAM 0115).
- Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer
- Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer
- Impact of the COVID-19 pandemic on stage at diagnosis of patients with breast cancer: An analysis of 11,752 patients from Oncoclínicas.
- Adjuvant therapy for HR+/HER2- early-stage breast cancer (EBC): Changes in practice patterns among community oncologists in Brazil.
- Cost-effectiveness of breast, lung, colon, prostate and cervical cancer outcomes in Brazil: a worldwide comparison
- The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)
- Real-world survival outcomes associated with use of pertuzumab and trastuzumab emtansine (T-DM1) for HER2-positive (HER2+) metastatic breast cancer (MBC) in Brazilian private healthcare setting.
- Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology
- Perspectives on the Systemic Staging in Newly Diagnosed Breast Cancer
- Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: A Brazilian public health care system perspective
- ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
- Prevalência da mutação do gene do receptor de estrogênio (ESR1) em pacientes com câncer de mama tratadas com terapia endócrina neoadjuvante
- Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer
- Lack of access to CDK4/6 inhibitors for premenopausal patients with metastatic breast cancer in Brazil: estimation of the number of premature deaths
- Abstract OT3-07-01: Real-World Data on First-line Treatment of HR-positive, HER2-negative, Metastatic Breast Cancer in Brazil (BRAVE Study/LACOG 0221)
- 1577P Early mortality linked to COVID-19 in cancer patients as compared to historical control in pre-pandemic times
